Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium
By:
Acutus Medical, Inc. via
GlobeNewswire
December 29, 2022 at 06:00 AM EST
CARLSBAD, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston. This abstract – including full study results - will be presented on Friday, February 3, 2023. The AcQForce Flutter clinical study was submitted to the FDA as part of Acutus’ PMA submission for the AcQBlate Force Sensing Ablation Catheter, the only force-sensing ablation catheter with a gold tip electrode, and System. The irrigated gold tip ablation catheter has 4x thermal conductivity compared to platinum catheters, which allows for significantly more energy delivery at a lower temperature and requires less saline flow.1 This is the first PMA submission by Acutus and the first time the company is presenting at a Late-Breaking Clinical Trials session. To learn more about Acutus Medical’s complete portfolio of diagnostic, access and therapy products, please visit https://acutusmedical.com. References About Acutus Medical About AF Symposium Follow Acutus Medical on: Twitter, LinkedIn, YouTube and Facebook. Investor Contact Media Contact
More NewsView More
Warner Bros. Sale Rumors Heat Up: What Investors Need to Know ↗
Today 18:23 EST
Via MarketBeat
From Science Project to Solvent: WeRide’s 761% Revenue Surge ↗
Today 17:48 EST
Via MarketBeat
Via MarketBeat
Recent QuotesView More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
|
